Publications by authors named "Maximilian Einsiedler"
Article Synopsis
- - The study investigates the best treatment escalation strategy for patients with relapsing-remitting multiple sclerosis (RRMS) already on low-efficacy disease modifying therapies (DMT), utilizing data from the Swiss National Treatment Registry.
- - Researchers matched 450 patients who switched to either medium- or high-efficacy DMTs and compared their relapse rates and disability progression.
- - Findings revealed that transitioning directly to high-efficacy DMTs resulted in significantly lower relapse rates compared to medium-efficacy DMTs or no treatment escalation, suggesting that immediate high-efficacy treatment is preferable.
Background: Anti-CD20 monoclonal antibodies are recently introduced treatments in progressive MS and real-world data are lacking.
Objective: The aim of this study is to describe a cohort of progressive MS patients treated with ocrelizumab or rituximab in a real-world setting.
Methods: This monocentric prospective cohort study at the University Hospital of Strasbourg included patients with primary progressive or secondary progressive MS that started treatment with anti-CD20 antibodies before June 2019.
Background: The recent lockdown due to the COVID-19 pandemic has been linked to a higher incidence of psychiatric manifestations and substance abuse. The recreative use of nitrous oxide is more and more widespread and neurological complications are frequent.
Methods: We report clinical characteristics and biological findings of five consecutive patients presenting to our tertiary care center between April 2020 and February 2021 with various neurological symptoms occurring after recent nitrous oxide abuse.